Fungal persister cells: The basis for recalcitrant infections?
Open accessThe DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Persister cells are a small subpopulation within fungal biofilms that are highly resistant to high concentrations of antifungals and therefore most likely contribute to the resistance and recalcitrance of biofilm infections. Moreover, this subpopulation is defined as a nongrowing, phenotypic variant of wild-type cells that can survive high doses of antifungals. There are high degrees of heterogeneity and plasticity associated with biofilm formation, resulting in a strong variation in the amount of persister cells. The fraction of these cells in fungal biofilms also appear to be dependent on the type of substrate. The cells can be observed immediately after their adhesion to that substrate, which makes up the initial step of biofilm formation. Thus far, persister cells have primarily been studied in Candida spp. These fungi are the fourth most common cause of nosocomial systemic infections in the United States, with C. albicans being the most prevalent species. Remarkably, persisters exhibit characteristics of a dormant state similar to what is observed in cells deprived of glucose. This dormant state, together with attachment to a substrate, appears to provide the cells with characteristics that help them overcome the challenges with fungicidal drugs such as amphotericin B (AmB). AmB is known to induce apoptosis, and persister cells are able to cope with the increase in reactive oxygen species (ROS) by activating stress response pathways and the accumulation of high amounts of glycogen and trehalose-two known stress-protecting molecules. In this review, we discuss the molecular pathways that are involved in persister cell formation in fungal species and highlight that the eradication of persister cells could lead to a strong reduction of treatment failure in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Whereas tolerance is generally due to substantial subpopulations of cells (5-90%) that grow in drug, antifungal heteroresistance or persistence involve rare cells (generally <<1%) that transiently survive high concentrations of antifungal drugs14.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“biofilms are known to hinder the penetration of antifungal drugs and host immune effectors and also trigger the formation of Candida persister cells, leading to poor clinical outcomes [52,53].”
From Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs (2020) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is difficult to detect persisters in planktonic cells, which is different from bacteria [12,16].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One possible explanation is antifungal persistence, given its ability to survive lethal drug exposure without an increase of resistance level [12].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Fungal persisters are dormant variants of wild-type cells that are tolerant to antifungal drugs, surviving high dosage of antifungals that exceed the minimal inhibitory concentration (MIC) [12,16].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [12]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Maisonneuve, E., Castro-Camargo, M., & Gerdes, K. (2013) · Cell · doi:10.1016/j.cell.2013.07.048 · Cited by 438
RetractedIn situ click chemistry generation of cyclooxygenase-2 inhibitors
Bhardwaj, A., Kaur, J., Wuest, M., & Wuest, F. (2017) · Nature Communications · doi:10.1038/s41467-016-0009-6 · Cited by 7,448
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Azevedo, R. S. S., de Sousa, J. R., Araujo, M. T. F., Martins Filho, A. J., de Alcantara, B. N., Araujo, F. M. C., Queiroz, M. G. L., Cruz, A. C. R., Vasconcelos, B. H. B., Chiang, J. O., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17765-5 · Cited by 3,478
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Candida albicans pathogenicity mechanisms
Mayer, F. L., Wilson, D., & Hube, B. (2013) · Virulence · doi:10.4161/viru.22913 · Cited by 1,848
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
TREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION
Bigger, J. (1944) · The Lancet · doi:10.1016/s0140-6736(00)74210-3 · Cited by 1,178
Cited by
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Bacterial Persisters and Infection: Past, Present, and Progressing
Gollan, B., Grabe, G., Michaux, C., & Helaine, S. (2019) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115650 · Cited by 280
Candida albicans biofilms and polymicrobial interactions
Ponde, N. O., Lortal, L., Ramage, G., Naglik, J. R., & Richardson, J. P. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1843400 · Cited by 281
“Patients with long-term oral carriage of C. albicans have a higher incidence of persister cells (LaFleur et al. 2010), suggesting that persister cells may be relevant in the context of continual colonisation or recurrent infections in vivo (Wuyts et al. 2018).”
BackgroundCandidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
“18,19 The development of IC induces a response from all arms of the immune system.”
Evolutionary causes and consequences of bacterial antibiotic persistence
Bakkeren, E., Diard, M., & Hardt, W.-D. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0378-z · Cited by 224
The importance of antimicrobial resistance in medical mycology
Gow, N. A. R., Johnson, C., Berman, J., Coste, A. T., Cuomo, C. A., Perlin, D. S., Bicanic, T., Harrison, T. S., Wiederhold, N., Bromley, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32249-5 · Cited by 224
Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
Faustino, C., & Pinheiro, L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12010029 · Cited by 203
“Fungal biofilms are surface-associated communities of microbial cells protected by an extracellular polysaccharide-rich matrix that inhibits diffusion and cell uptake of antimicrobial agents [11,12,15].”
BackgroundAntimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy
Mercer, D. K., Torres, M. D. T., Duay, S. S., Lovie, E., Simpson, L. W., von Köckritz‐Blickwede, M., de la Fuente‐Núñez, C., O′Neil, D. A., & Angeles-Boza, A. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00326 · Cited by 152
“, persister cells and/or SCV within biofilms (Mirani et al., 2015; Waters et al., 2016; Wuyts et al., 2018; Yan and Bassler, 2019).”
BackgroundInfluentialFan, F., Liu, Y., Liu, Y., Lv, R., Sun, W., Ding, W., Cai, Y., Li, W., Liu, X., & Qu, W. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106673 · Cited by 159
Pathogenesis and Clinical Relevance of Candida Biofilms in Vulvovaginal Candidiasis
Rodríguez‐Cerdeira, C., Martínez-Herrera, E. O., Carnero-Gregorio, M., López-Bárcenas, A., Fabbrocini, G., Fida, M., El-Samahy, M., & González-Cespón, J. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.544480 · Cited by 142
Adapting to survive: How Candida overcomes host-imposed constraints during human colonization
Alves, R. M. A., Barata-Antunes, C., Casal, M., Brown, A. J. P., Dijck, P. V., & Paiva, S. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008478 · Cited by 135
The role of Lactobacillus species in the control of Candida via biotrophic interactions
Zangl, I., Pap, I.-J., Aspöck, C., & Schüller, C. (2020) · Microbial Cell · doi:10.15698/mic2020.01.702 · Cited by 123
Therapeutic Challenges of Non- Aspergillus Invasive Mold Infections in Immunosuppressed Patients
Lamoth, F., & Kontoyiannis, D. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01244-19 · Cited by 106
Multi-omics tools for studying microbial biofilms: current perspectives and future directions
Seneviratne, C. J., Suriyanarayanan, T., Widyarman, A. S., Lee, L. S., Lau, M., Ching, J., Delaney, C., & Ramage, G. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1828817 · Cited by 98
“1942; Bioger 1944) and more recently in Escherichia coli, Pseudomonas aeruginosa, Lactobacillus acidophilus, and Candida species (Jayaraman 2008; Mulcahy et al. 2010; Sun et al. 2016; Van den Bergh et al. 2017; Wuyts et al. 2018).”
BackgroundFungal biofilms in human health and disease
Ramage, G., Kean, R., Rautemaa-Richardson, R., Williams, C., & Lopez-Ribot, J. L. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01147-0 · Cited by 72
Linking Cellular Morphogenesis with Antifungal Treatment and Susceptibility in Candida Pathogens
Sharma, J., Rosiana, S., Razzaq, I., & Shapiro, R. S. (2019) · Journal of Fungi · doi:10.3390/jof5010017 · Cited by 77
“These persister cells may be involved in antifungal tolerance and recalcitrant infections [181].”
BackgroundEradication of Candida albicans persister cell biofilm by the membranotropic peptide gH625
Galdiero, E., de Alteriis, E., De Natale, A., D’Alterio, A., Siciliano, A., Guida, M., Lombardi, L., Falanga, A., & Galdiero, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-62746-w · Cited by 65
Rao, H., Choo, S., Mahalingam, S. R. R., Adisuri, D. S., Madhavan, P., Akim, A. M., & Chong, P. P. (2021) · Molecules · doi:10.3390/molecules26071870 · Cited by 73
“Antimicrobial tolerance is the ability of microorganisms to survive transient exposure to high concentrations of antibiotics that exceed the minimum inhibitory concentration (MIC) [86], which could lead to treatment failure.”
BackgroundInfluentialPower-law tail in lag time distribution underlies bacterial persistence
Şimşek, E., & Kim, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903836116 · Cited by 68
Phloroglucinol and Its Derivatives: Antimicrobial Properties toward Microbial Pathogens
Khan, F., Tabassum, N., Bamunuarachchi, N. I., & Kim, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c00532 · Cited by 59
Arastehfar, A., Daneshnia, F., Cabrera, N., Penalva-Lopez, S., Sarathy, J., Zimmerman, M., Shor, E., & Perlin, D. S. (2023) · Nature Communications · doi:10.1038/s41467-023-36882-6 · Cited by 58
Eldesouky, H. E., Salama, E. A., Li, X., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64571-7 · Cited by 55
Biofilm: The invisible culprit in catheter-induced candidemia
Wijaya, M., Halleyantoro, R., & Kalumpiu, J. F. (2023) · AIMS Microbiology · doi:10.3934/microbiol.2023025 · Cited by 59
de Alteriis, E., Maione, A., Falanga, A., Bellavita, R., Galdiero, S., Albarano, L., Salvatore, M. M., Galdiero, E., & Guida, M. (2021) · Antibiotics · doi:10.3390/antibiotics11010026 · Cited by 54
“Persisters have been detected in biofilms of different Candida species [10,13] and represent a small fraction of the sessile population in the biofilm.”
BackgroundBiofilm formation in clinically relevant filamentous fungi: a therapeutic challenge
Roudbary, M., Vahedi‐Shahandashti, R., dos Santos, A. L. S., Mohammadi, S. R., Aslani, P., Lass‐Flörl, C., & Rodrigues, C. F. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1950121 · Cited by 51
Owumi, S. E., Irozuru, C. E., Arunsi, U. O., & Oyelere, A. K. (2022) · Toxicon · doi:10.1016/j.toxicon.2021.12.021 · Cited by 46
Sheehan, G., Konings, M., Lim, W., Fahal, A. H., Kavanagh, K. A., & van de Sande, W. W. J. (2020) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0008190 · Cited by 41
Eldesouky, H. E., Lanman, N. A., Hazbun, T. R., & Seleem, M. N. (2020) · Virulence · doi:10.1080/21505594.2020.1838741 · Cited by 37
“penetration of antifungal drugs and host immune effectors and also trigger the formation of Candida persister cells, leading to poor clinical outcomes [52,53].”
BackgroundTrichosporon asahii and Trichosporon inkin biofilms produce antifungal-tolerant persister cells
Cordeiro, R. D. A., Aguiar, A. L. R., da Silva, B. N., Pereira, L. M. G., Portela, F. V. M., de Camargo, Z. P., de Lima-Neto, R. G., Castelo-Branco, D. D. S. C. M., Rocha, M. F. G., & Sidrim, J. J. C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.645812 · Cited by 34
“Previous studies have shown that MIC values for AMB against Trichosporon biofilm-cells were, in general, below 50 µg/mL (Iturrieta-González et al., 2014; Cordeiro et al., 2015; Montoya et al., 2018).”
BackgroundResultInfluentialButassi, E., Svetaz, L. A., Carpinella, M. C., Efferth, T., & Zacchino, S. A. (2021) · Antibiotics · doi:10.3390/antibiotics10091053 · Cited by 43
“produce a 40% mortality rate [2,9], while cryptococcosis and aspergillosis produce a mortality rate between 20% to 90% [9].”
BackgroundThe role of the Candida biofilm matrix in drug and immune protection
Roy, S., & Gow, N. A. R. (2023) · The Cell Surface · doi:10.1016/j.tcsw.2023.100111 · Cited by 35
“These dormant cells exhibit properties that are similar to glucose-starved planktonic cells whose physiology enables them to survive challenge with fungicidal drugs by inducing stress tolerance pathways and protective levels of internal glycogen and trehalose (Wuyts et al., 2018).”
BackgroundControl of bacterial and fungal biofilms by natural products of Ziziphus joazeiro Mart. (Rhamnaceae)
Andrade-Pinheiro, J. C., da Silva, A. R. P., de Freitas, M. A., Ramos, B. D. A., de Freitas, T. S., dos Santos, F. D. A. G., de Andrade, M. C. L., Nunes, M., Tintino, S. R., da Silva, M. V., et al. (2019) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2019.06.006 · Cited by 37
Novel Therapies for Biofilm-Based Candida spp. Infections
Černáková, L., Light, C. J., Salehi, B., Rogel-Castillo, C., Victoriano, M., Martorell, M., Sharifi‐Rad, J., Martins, N. A., & Rodrigues, C. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/5584_2019_400 · Cited by 38
Targeting intrinsic cell death pathways to control fungal pathogens
Kulkarni, M., Stolp, Z. D., & Hardwick, J. M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.012 · Cited by 32
“Counter intuitively, slow growing fungal persister cells with decreased ergosterol or cell wall synthesis can be more tolerant to metabolic drug pressures [164].”
Richards, T. A., Massana, R., Pagliara, S., & Hall, N. (2019) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2019.0076 · Cited by 32
Aspergillus fumigatus escape mechanisms from its harsh survival environments
Liu, F., Zeng, M., Zhou, X., Huang, F., & Song, Z. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12952-z · Cited by 33
“Therefore, fungal cells cannot contact the high concentrations of drugs so they can survive (Wuyts et al. 2018).”
New perspectives on the topical management of recurrent candidiasis
Ré, A. C. D. S., Martins, J. F., Filho, M. C., Gelfuso, G. M., Aires, C. P., & Gratieri, T. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00901-0 · Cited by 49
Pérez, L., García, M. T., Pinazo, A., Pérez-Matas, E., Hafidi, Z., & Bautista, E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122602 · Cited by 29
“Antimicrobial treatment may kill metabolically active cells in biofilms, but without affecting persister cells, which can re-start colonization and biofilm development when the treatment is removed [11].”
BackgroundOxidative imbalance in Candida tropicalis biofilms and its relation with persister cells
da Silva, M. A., Baronetti, J. L., Páez, P. L., & Paraje, M. G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.598834 · Cited by 28
“However, the mechanism of PC formation is not well understood, and conflicting findings have been reported concerning their presence and metabolic state (Balaban et al., 2013; Maisonneuve and Gerdes, 2014; Wuyts et al., 2018).”
BackgroundEl-Ganiny, A. M., Kamel, H. A., Yossef, N. E., Mansour, B., & El-Baz, A. M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.01.011 · Cited by 30
“Biofilm formation is an important virulence factor in pathogenic fungi that also contributes to the development of drug resistance (Wuyts et al., 2018).”
Heredero‐Bermejo, I., Gómez-Casanova, N., Quintana, S., Soliveri, J., de la Mata, F. J., Pérez‐Serrano, J., Sánchez‐Nieves, J., & Copa-Patiño, J. L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100918 · Cited by 28
Schroeder, J. A., Wilson, C. M., & Pappas, P. G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.007 · Cited by 31
Antifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
“Persister fungi. another mechanism underlying phenotypical heterogeneity involves persister cells. within a fungal popula‑ tion, a small fraction of cells enter a dormant state, becoming persister cells (10,84).”
InfluentialDumeaux, V., Massahi, S., Bettauer, V., Mottola, A., Dukovny, A., Khurdia, S. S., Costa, A. C. B. P., Omran, R. P., Simpson, S., Xie, J. L., et al. (2023) · eLife · doi:10.7554/elife.81406 · Cited by 25
Aspergillus fumigatus Can Display Persistence to the Fungicidal Drug Voriconazole
Scott, J., Valero, C., Mato-López, Á., Donaldson, I. J., Roldán, A., Chown, H., Van Rhijn, N., Lobo-Vega, R., Gago, S., Furukawa, T., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04770-22 · Cited by 24
El Meouche, I., Jain, P., Jolly, M. K., & Capp, J.-P. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102069 · Cited by 22
“As many antifungal drugs act on activating growing cells, fungal persister cells are thought to be in an inactive dormant state and be less metabolically active[76].”
BackgroundInfluentialPalková, Z., & Váchová, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.10.012 · Cited by 22
DC-SIGN targets amphotericin B-loaded liposomes to diverse pathogenic fungi
Ambati, S., Pham, T., Lewis, Z., Lin, X., & Meagher, R. B. (2021) · Fungal Biology and Biotechnology · doi:10.1186/s40694-021-00126-3 · Cited by 20
“, persister cells) may necessitate extended treatments in vivo [38].”
BackgroundThe intricate link between iron, mitochondria and azoles in Candida species
Genechten, W. V., Vergauwen, R., & Dijck, P. V. (2023) · FEBS Journal · doi:10.1111/febs.16977 · Cited by 25
“…the abundance of mitochondria, the presence of the mitochondrial membrane potential, aconitase activity as this could provide insight in the supra-MIC growth of C. albicans , the lethality of the combination therapy of doxycycline and azoles, and even the possible formation of persister cells [86].”
Harding, M. W., Nadworny, P. L., Buziak, B., Omar, A., Daniels, G. C., & Feng, J. (2019) · Molecules · doi:10.3390/molecules24122312 · Cited by 19
“Testing fungicide efficacy versus biofilms frequently reveals that biofilms are much more tolerant of chemical treatments [18,30].”
BackgroundChromatin Structure and Drug Resistance in Candida spp.
O’Kane, C. J., Weild, R., & M. Hyland, E. (2020) · Journal of Fungi · doi:10.3390/jof6030121 · Cited by 18
“This is especially true for fungal persister cells, which are thought to be in an inactive dormant state [87].”
BackgroundA Cecropin-4 Derived Peptide C18 Inhibits Candida albicans by Disturbing Mitochondrial Function
Sun, C., Peng, J., Yang, L., Jiao, Z.-L., Zhou, L., Tao, R., Zhu, L., Tian, Z., Huang, M., & Guo, G. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.872322 · Cited by 20
Gómez-Casanova, N., Lozano‐Cruz, T., Soliveri, J., Gómez, R., Ortega, P., Copa-Patiño, J. L., & Heredero‐Bermejo, I. (2021) · Journal of Fungi · doi:10.3390/jof7070574 · Cited by 17
“We found cells that persisted when cell suspensions were plated on agar plates [55,56].”
BackgroundDasilva, M. A., Andrada, K. F. C., Torales, M. M., Hughes, I. M., Pez, P., García-Martínez, J. C., & Paraje, M. G. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02415-6 · Cited by 16
“It is known that Candida PCs have not been detected in planktonic cultures as they appear to be specific to biofilms and have a range of variability between 0.012 and 2% that may be explained, at least in part, by the surface type of the formation of a biofilm [6, 32, 46].”
BackgroundMethodInfluentialde Lapena, S. A. B., Garcia, M. T., Ward, R. A. D. C., Rossoni, R. D., Melo, V. M. M., & Junqueira, J. C. (2022) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2022.102837 · Cited by 18
Argüelles, A., Sánchez-Fresneda, R., Guirao-Abad, J. P., Belda-Iniesta, C., Lozano, J. A., Solano, F., & Argüelles, J. C. (2020) · Microorganisms · doi:10.3390/microorganisms8050749 · Cited by 16
“As an alternative, the presence of minority cells that possess intrinsic resistance (persister cells) might be operative [25] or the possible inactivation of at least one extract.”
BackgroundResveratrol-coated gold nanorods produced by green synthesis with activity against Candida albicans
do Carmo, P. H. F., Lage, A. C. P., Garcia, M. T., da Silva, N. S., Santos, D. A., Mylonakis, E. E., & Junqueira, J. C. (2024) · Virulence · doi:10.1080/21505594.2024.2416550 · Cited by 16
“The pathogenicity of C. albicans is associated with hyphal formation, secretion of proteolytic enzymes, haemolytic activity, and biofilm formation [4,5].”
BackgroundResearch advances and public health strategies in China on WHO priority fungal pathogens
Wang, Y., Han, L., Gong, J., Liu, L., Miao, B., & Xu, J. (2025) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2025.2561612 · Cited by 15
“Persisters enter a dormant or quiescent state during antifungal treatment, but they are not mutated and can resume growth once the drug is removed (Wuyts et al. 2018).”
Endurance of extremely prolonged nutrient prevention across kingdoms of life
Hazan, R., Schoemann, M., & Klutstein, M. (2021) · iScience · doi:10.1016/j.isci.2021.102745 · Cited by 16
The impact of phenotypic heterogeneity on fungal pathogenicity and drug resistance
Kozubowski, L., & Berman, J. G. (2025) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf001 · Cited by 14
“The term “persistence” also was used to refer to a small subpopulation of non-growing cells found in Candida spp. biofilms upon exposure to amphotericin B, a drug considered fungicidal (Wuyts et al. 2018 ).”
Geerts, N., Vooght, L. D., Passaris, I., Delputte, P., den Bergh, B. V., & Cos, P. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02701-22 · Cited by 14
Fungal quorum-sensing molecules and antiseptics: A promising strategy for biofilm modulation?
Marcomini, E. K., & Negri, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103624 · Cited by 15
Exopolysaccharides and Biofilms
Mauff, F. L. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_199 · Cited by 15
Metabolomic and Proteomic Changes in Candida albicans Biofilm in Response to Zosteric Acid Treatment
Cattò, C., Corte, L., Roscini, L., Cardinali, G., Villa, F., & Cappitelli, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214067 · Cited by 13
“Fungi form recalcitrant biofilms in many settings, with relevant consequences in terms of health, social and economic impact [1].”
BackgroundDeletion of CDR1 reveals redox regulation of pleiotropic drug resistance in Candida glabrata
Galkina, K. V., Okamoto, M., Chibana, H., Кнорре, Д. А., & Kajiwara, S. (2019) · Biochimie · doi:10.1016/j.biochi.2019.12.002 · Cited by 13
Antifungal persistence: Clinical relevance and mechanisms
Wang, R., Lv, J., Chen, L., Zhao, Y., & Du, H. (2025) · PLoS pathogens · doi:10.1371/journal.ppat.1013456 · Cited by 12
“Fungal persisters are dormant variants of wild-type cells that are tolerant to antifungal drugs, surviving high dosage of antifungals that exceed the minimal inhibitory concentration (MIC) [12,16].”
InfluentialSquitieri, D., Rizzo, S., Torelli, R., Mariotti, M., Sanguinetti, M., Cacaci, M., & Bugli, F. (2025) · Pharmaceuticals · doi:10.3390/ph19010008 · Cited by 12
“Sessile cells withstand drug concentrations many times higher than planktonic counterparts due to structural, metabolic, and physiological adaptations [154–156].”
Hostile Environments: Modifying Surfaces to Block Microbial Adhesion and Biofilm Formation
Wilkinson, D., Váchová, L., & Palková, Z. (2025) · Biomolecules · doi:10.3390/biom15060754 · Cited by 11
“The production of persisters depends on cell adherence and surface material, and the number of persister cells remains stable as the biofilm grows [36].”
Fluorescent toys ‘n’ tools lighting the way in fungal research
Genechten, W. V., Dijck, P. V., & Demuyser, L. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab013 · Cited by 16
Owumi, S. E., Ajakaiye, B., Akinwunmi, A. O., Nwozo, S. O., & Oyelere, A. K. (2023) · Molecules · doi:10.3390/molecules28073013 · Cited by 12
Aboualigalehdari, E., Tahmasebi Birgani, M., Fatahinia, M., & Hosseinzadeh, M. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.651221 · Cited by 11
“Several phenomena are implicated in biofilm resistance, including increased metabolic activity, production of extracellular biofilm matrix, cell density, upregulation of drug efflux pumps, persister cells, and stress responses (Piekarska et al., 2008; Li et al., 2015; Wuyts et al., 2018; Galdiero et al., 2020).”
BackgroundPan, M., Wang, Q., Cheng, T., Wu, D., Wang, T., Yan, G., & Shao, J. (2021) · Biofouling · doi:10.1080/08927014.2021.1985473 · Cited by 10
“Fungal persister cells are a dormant state with low activity and slow proliferation, and resist anti-fungal drugs (Wuyts et al. 2018), with several gene mutations increasing resistance to C. albicans.”
BackgroundInhibition of Candida glabrata Biofilm by Combined Effect of Dendritic Compounds and Amphotericin
Gómez-Casanova, N., Torres-Cano, A., Elias-Rodriguez, A. X., Lozano‐Cruz, T., Ortega, P., Gómez, R., Pérez‐Serrano, J., Copa-Patiño, J. L., & Heredero‐Bermejo, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081604 · Cited by 9
“These types of cells are a recognized problem associated with high resistance of biofilms and the incidence of biofilm-related infections, because this group of cells can survive against high doses of antifungals [4,25].”
BackgroundAdvancing Antimicrobial Resistance Research Through Quantitative Modeling and Synthetic Biology
Farquhar, K. S., Flohr, H., & Charlebois, D. A. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.583415 · Cited by 9
“Targeting this phenomenon will be important for mitigating AMR, as some non-genetically drugresistant pathogens are not easily detected by standard laboratory tests (Sears and Schwartz, 2017) and non-genetic drug resistance may be associated with the failure of antimicrobial therapies (Ben-Ami et al., 2016; Wuyts et a…”
BackgroundEradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand
Lanni, A., Iacobino, A., Fattorini, L., & Giannoni, F. (2023) · Microorganisms · doi:10.3390/microorganisms11061511 · Cited by 11
“) [22], and protozoa (Plasmodium, Leishmania, Trypanosoma and Toxoplasma spp.”
BackgroundFacing Foodborne Pathogen Biofilms with Green Antimicrobial Agents: One Health Approach
Godínez, A. K. K., Villicaña, C., Heredia, J. B., Valdez-Torres, J. B., Muy‐Rangel, M. D., & León‐Félix, J. (2025) · Molecules · doi:10.3390/molecules30081682 · Cited by 10
“Persister cells: These are phenotypic variants within bacterial and fungal biofilms that exhibit high tolerance to antimicrobial agents, contributing to the recalcitrance of biofilm-associated infections [67,68].”
Overcoming Candida biofilm resistance: targeting persister cells with probiotic-derived metabolites
Debta, P., Sahu, B. K., Patra, S. K., Debta, F. M., Mishra, E., & Panda, S. K. (2026) · Frontiers in Antibiotics · doi:10.3389/frabi.2026.1767028 · Cited by 8
“To prevent relapse, strategies targeting metabolic dormancy, stress-response buffering (Hsp90/calcineurin), ROS detoxi fi cation, or matrix-associated protection are being actively investigated as supplements to standard antifungal regimens (Wuyts et al., 2018; Robbins et al., 2011).”
InfluentialSinoca, M., Maione, A., Gambino, E., Imparato, M., Galdiero, M., de Alteriis, E., Galdiero, E., & Guida, M. (2024) · Biomedicines · doi:10.3390/biomedicines12020389 · Cited by 7
“Persistent cells are a phenotypic variant of wild-type cells not in active growth, capable of surviving at high concentrations of antimicrobials [13].”
BackgroundRetinoids as Alternative Antifungal Agents Against Candida albicans: In Vitro and In Silico Evidence
Cosio, T., Romeo, A., Pistoia, E. S., Pica, F., Freni, C., Iacovelli, F., Orlandi, A., Falconi, M., Campione, E., & Gaziano, R. (2025) · Microorganisms · doi:10.3390/microorganisms13020237 · Cited by 7
“These findings suggest that retinoids, either alone or combined with current conventional antifungal drugs, could represent very promising compounds to design novel therapeutic or preventive antifungal strategies against C. albicans .”
Pérez-Vielma, N. M., Gómez‐López, M., Martínez–Godínez, M. D. L. Á., Torres, A. L. L., Domínguez‐López, A., & Miliar-García, Á. (2024) · Clinics and Practice · doi:10.3390/clinpract14020031 · Cited by 9
“In addition, the pharmacological resistance of Candida has been shown to initially depend on the concentration and type of drug used as well as the immunological capacity of the infected individual [44].”
BackgroundAguiar, A. L. R., da Silva, B. N., Fiallos, N. D. M., Pereira, L. M. G., Silva, M. L., de Souza, P. D. F. S. M., Portela, F. V. M., Sidrim, J. J. C., Rocha, M. F. G., Castelo‐Branco, D. D. S. C. M., et al. (2023) · Biofouling · doi:10.1080/08927014.2023.2202315 · Cited by 6
“As fungal persister cells have been associated to recalcitrant infections (Wuyts et al. 2018; Galdiero et al. 2020), the search of antipersister molecules is urgent and necessary.”
BackgroundKumar, A., Francis, A., Hans, S., & Thakur, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4909-6_8 · Cited by 7
The Influence of Cellulose-Type Formulants on Anti-Candida Activity of the Tyrocidines
Masoudi, Y., van Rensburg, W., Barnard-Jenkins, B., & Rautenbach, M. (2021) · Antibiotics · doi:10.3390/antibiotics10050597 · Cited by 6
“These persister cells tend to shift their metabolism to carbon storage and down-regulate glycolysis [50,52], and are therefore geared towards anabolism.”
BackgroundStrydom, M. B., Nelson, T. M., Khan, S. A., Walpola, R. L., Ware, R. S., & Tiralongo, E. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04999-1 · Cited by 6
Farnesol functionalized chitosan-gold nanocomposites for disruption of fungal biofilms
Kumar, A., Yadav, E., Yadav, B., Nanda, D., Meena, A. S., Yadav, S. P. S., Poluri, K. M., & Gupta, P. (2025) · Materials Today Chemistry · doi:10.1016/j.mtchem.2025.103079 · Cited by 5
SNOR promotes translation restart after dormancy
Gluc, M., Rosa, H., Bożko, M., Turner, L. A., Prince, C. R., Peskova, Y. B., Feaga, H. A., Gould, K. L., Matteï, S., & Jomaa, A. (2026) · Nature · doi:10.1038/s41586-026-10530-7 · Cited by 7
Poudyal, N. R., Mehlem, R., Doneparthi, P., Cady, T., Kaufman, G., Willger, S. D., Ortiz, M., Noorai, R. E., Stajich, J., & Dhingra, S. (2026) · Genetics · doi:10.1093/genetics/iyag152 · Cited by 5
“Additionally, biofilms can lead to persister cells (Wuyts et al. 2018).”
Nature-derived gelatin-based antifungal nanotherapeutics for combatting Candida albicans biofilms
Nabawy, A. M., Makabenta, J. M., Park, J., Huang, R., Nayar, V., Patel, R., & Rotello, V. M. (2023) · Environmental Science Nano · doi:10.1039/d3en00372h · Cited by 6
Synergistic Effect of Hydralazine Associated with Triazoles on Candida spp. in Planktonic Cells
do Nascimento, F. B. S. A., Sá, L. G. D. A. V., Neto, J. B. D. A., Moreno, L. S. S., Queiroz, H. A., da Silva, L. J., Cabral, V. P. D. F., Rodrigues, D. S., Pereira, S. S., Cavalcanti, B. C., et al. (2023) · Future Microbiology · doi:10.2217/fmb-2023-0012 · Cited by 5
Unlocking the enigma of phenotypic drug tolerance: Mechanisms and emerging therapeutic strategies
Mishra, A. K., Thakare, R., Santani, B. G., Yabaji, S. M., Dixit, S. K., & Srivastava, K. K. (2023) · Biochimie · doi:10.1016/j.biochi.2023.12.009 · Cited by 5
Silva, S. D. M., Echeverri, C. R., Mendes‐Giannini, M. J. S., Fusco‐Almeida, A. M., & González, Á. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100246 · Cited by 6
“Furthermore, cells derived from biofilms, known as “ Persisters, ” are inherently much more resistant to antifungals and have been demonstrated in fungi such as Saccharomyces cerevisiae and Candida albicans (Bojsen et al., 2016; LaFleur et al., 2006; Wuyts et al., 2018).”
BackgroundAyed, R. B., Bouzid, M., Zbidi, R., Aouioua, M., Gargouri, A. F., Belghith, H., & Romdhane, I. B.-B. (2022) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-022-03864-1 · Cited by 5
Polymicrobial biofilms: Impact on fungal pathogenesis
Costa-Orlandi, C. B., Bila, N. M., Vaso, C. O., Pires, A. C. M. D. S., Silva, S. D. M., Medina‐Alarcón, K. P., Marcos, C. M., Fusco‐Almeida, A. M., & Mendes‐Giannini, M. J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99977-9.00040-5 · Cited by 9
Harrington, A. A., Nickels, T. J., & Cunningham, K. W. (2026) · mBio · doi:10.1128/mbio.02546-25 · Cited by 4
“Though there is concern that tolerance and persistence will contribute to therapeutic failure, relapse, and perhaps even the acquisition of resistance (30, 44), the regulatory mechanisms behind these phenomena have been understudied in fungal pathogens of humans.”
Sonoporation-enhanced the antibacterial efficacy of aminoglycosides against Gram-negative persisters
Chen, H., Wang, J., Han, F., Guo, C., Fu, X., Zhang, Z., & Song, Y. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04414-7 · Cited by 4
“…manifesting not only in bacteria such as E. coli (Balaban et al. 2004; Harms et al. 2016), P. aeruginosa (Costerton et al. 1999) , S. aureus (Lister and Horswill 2014) and M. tuberculosis (Ehrt et al. 2018), but also in fungi (Wuyts et al. 2018) like Candida tropicalis (Mayer et al. 2013).”
CRISPR-driven strategies to disrupt methicillin-resistant Staphylococcus aureus biofilms: a review
Nuevo, J. J. M., Fortaleza, J. A. G., Cabuhat, K. S. P., Ong, C. J. N., Jalova, A. C., Mortel, F. A., & Bacalzo, G. D. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1784529 · Cited by 4
“The bio fi lm environment further enhances persister survival by limiting both antibiotic exposure and immune clearance (Karkhur et al., 2025; Wuyts et al., 2018; Cordeiro et al., 2021).”
Ye, M., Chen, H., Liu, C., Ren, A.-J., Yang, H., & Wang, S.-S. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15718 · Cited by 4
“, 2018), are known to be highly resistant to conventional antimicrobial agents, such as amphotericin B, chlorohexidine and miconazole (Bink et al., 2011; LaFleur et al., 2006; Wuyts et al., 2018).”
BackgroundInfluentialLiu, G., Yan, Y., Yang, G., Duan, S., Yuan, P., Zhang, S., Li, F., Gao, X., & Nakanishi, H. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00897-22 · Cited by 4
The Baldwin Effect Reloaded: Intermediate Levels of Phenotypic Plasticity Favor Evolutionary Rescue
Lambert, A., Achaz, G., Rouzic, A. L., & Loison, L. (2025) · The American Naturalist · doi:10.1086/737198 · Cited by 6
Biocenosis of the vagina. Norm. Disruption. Restoration
Radzinskiy, V. E., Savicheva, A. M., Vorob'ev, S., Владимировна, С. Е., Shalepo, K. V., Budilovskaya, O. V., Husnutdinova, T., Krysanova, A. А., Guschin, A. E., Raevskaya, O., et al. (2023) · Publishing Center RIOR eBooks · doi:10.29039/978-5-907218-72-7 · Cited by 3
Metadata
- Authors
- Wuyts, J., Van Dijck, P., & Holtappels, M.
- Affiliations
- VIB-KU Leuven Center for Microbiology (BE)
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-10-18
- Volume
- 14
- Issue
- 10
- Pages
- e1007301
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC6193731
- OpenAlex
- W2897950718
- Cited by
- 136
- References
- 87
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 15 · 2023: 19 · 2022: 20 · 2021: 19 · 2020: 19 · 2019: 10
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Belgian Federal Science Policy Office
- KU Leuven (C14/17/063)
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Keywords
- fungal biofilms, antifungal resistance, recalcitrant infection, Candida albicans, Candida, amphotericin B resistance, dormancy, reactive oxygen species, stress response pathways, trehalose, glycogen, nosocomial fungal infections, treatment failure
- MeSH terms
- Antifungal Agents, Candida, Candidiasis, Cross Infection, Humans, Biofilms, Drug Resistance, Multiple, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.